Shebli Atrash, James Symanowski, Sarah Norek, Monica Plott, Robin Cox, Cecilia Flynn, Kelly Bumgarner, Darynne Rhinehardt, Xhevahire Begic, Reed Friend, Barry Paul, Cindy Varga, Christopher Ferreri, Mauricio Pineda-Roman, Manisha Bhutani, Peter M. Voorhees
{"title":"OA-57 贝兰他单抗-马法多(BelMaf)联合卡非佐米、来那度胺和地塞米松(KRd)治疗多发性骨髓瘤(MM)的 1 期临床试验结果","authors":"Shebli Atrash, James Symanowski, Sarah Norek, Monica Plott, Robin Cox, Cecilia Flynn, Kelly Bumgarner, Darynne Rhinehardt, Xhevahire Begic, Reed Friend, Barry Paul, Cindy Varga, Christopher Ferreri, Mauricio Pineda-Roman, Manisha Bhutani, Peter M. Voorhees","doi":"10.1016/S2152-2650(24)01898-6","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":"24 ","pages":"Page S36"},"PeriodicalIF":2.7000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"OA-57 Results of a Phase 1 Clinical Trial of Belantamab Mafadotin (BelMaf) Combined With Carfilzomib, Lenalidomide, and Dexamethasone (KRd) for Multiple Myeloma (MM) After One Prior Line of Therapy (LOT)\",\"authors\":\"Shebli Atrash, James Symanowski, Sarah Norek, Monica Plott, Robin Cox, Cecilia Flynn, Kelly Bumgarner, Darynne Rhinehardt, Xhevahire Begic, Reed Friend, Barry Paul, Cindy Varga, Christopher Ferreri, Mauricio Pineda-Roman, Manisha Bhutani, Peter M. Voorhees\",\"doi\":\"10.1016/S2152-2650(24)01898-6\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":10348,\"journal\":{\"name\":\"Clinical Lymphoma, Myeloma & Leukemia\",\"volume\":\"24 \",\"pages\":\"Page S36\"},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2024-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Lymphoma, Myeloma & Leukemia\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2152265024018986\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Lymphoma, Myeloma & Leukemia","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2152265024018986","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
OA-57 Results of a Phase 1 Clinical Trial of Belantamab Mafadotin (BelMaf) Combined With Carfilzomib, Lenalidomide, and Dexamethasone (KRd) for Multiple Myeloma (MM) After One Prior Line of Therapy (LOT)
期刊介绍:
Clinical Lymphoma, Myeloma & Leukemia is a peer-reviewed monthly journal that publishes original articles describing various aspects of clinical and translational research of lymphoma, myeloma and leukemia. Clinical Lymphoma, Myeloma & Leukemia is devoted to articles on detection, diagnosis, prevention, and treatment of lymphoma, myeloma, leukemia and related disorders including macroglobulinemia, amyloidosis, and plasma-cell dyscrasias. The main emphasis is on recent scientific developments in all areas related to lymphoma, myeloma and leukemia. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.